Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HSP90 peptide vaccine AST-021p

A cancer vaccine containing a peptide antigen derived from a specific protein heat shock protein 90 (HSP90) generated by tumor cells, with potential immunostimulating and antineoplastic activities. Upon vaccination, the HSP90 peptide vaccine may activate the immune system to induce an immune response against HSP90-expressing tumor cells. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	therapeutic cancer vaccine AST-021p
Code name:	AST 021p AST-021p AST021p

HSP90 peptide vaccine AST-021p

Search NCI's Drug Dictionary